Trials / Completed
CompletedNCT00259987
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus
A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase II study will assess the efficacy, safety, and pharmacodynamics and pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with relapsed adenocarcinoma of the esophagus, including tumors of the GE junction and gastric cardia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lapatinib (GW572016) oral tablets |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-05-01
- First posted
- 2005-12-01
- Last updated
- 2009-05-18
Locations
6 sites across 3 countries: United States, Netherlands, Peru
Source: ClinicalTrials.gov record NCT00259987. Inclusion in this directory is not an endorsement.